Anthem Biosciences, a Bengaluru-based contract research, development and manufacturing organization (CRDMO), has successfully raised Rs 1,016 crore from anchor investors ahead of its initial public offering scheduled to open for public subscription on July 14.
The company allocated 1.78 crore equity shares to 60 institutional funds at Rs 570 per share, representing the upper end of the IPO price band of Rs 540-570. This strong anchor investor response demonstrates significant institutional confidence in the pharmaceutical services company's growth prospects.
Strong Institutional Backing
The anchor book attracted prominent global and domestic investors, including Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, PineBridge Global Funds and Societe Generale. Major Indian mutual funds also participated, with HDFC MF, ICICI Prudential MF, Axis MF, UTI MF, Quant MF and Motilal Oswal MF securing allocations.
The Rs 3,395 crore IPO will remain open for public subscription from July 14 to July 16. As the offering is entirely an offer-for-sale structure, the company will not receive proceeds from the issue, with funds going directly to selling shareholders.
Integrated Pharmaceutical Services Platform
Anthem Biosciences operates as an innovation-driven and technology-focused CRDMO with fully integrated operations spanning the entire pharmaceutical value chain from drug discovery through development and manufacturing. The company has established expertise in manufacturing complex specialized fermentation-based active pharmaceutical ingredients.
The company's product portfolio includes probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars, positioning it within the growing market for specialized pharmaceutical ingredients and contract manufacturing services.
Market Position and Peers
Anthem Biosciences competes alongside established listed peers including Sai Life Sciences Ltd, Syngene International, Suven Life Sciences and Divi's Laboratories in the Indian pharmaceutical services sector. The company's integrated capabilities across the drug development and manufacturing spectrum differentiate its service offering in this competitive landscape.
JM Financial, Citigroup Global Markets India, J P Morgan India and Nomura Financial Advisory and Securities (India) are serving as book-running lead managers for the public offering.
